Skip to main content
. 2020 Feb 26;8(1):e000146. doi: 10.1136/jitc-2019-000146

Figure 4.

Figure 4

(A) Overall survival by BOR among all 8170 randomized patients. (B) Overall Survival by BOR among anti-PD-1/PD-L1-treated patients. BOR, best overall response. iCR/CR, complete response; iPR/PR, partial response; iSD/SD, stable disease; NE, not evaluable; PD, progression of disease.